Abstract | rheumatoid arthritis synovial fibroblasts (rAsFs) are the effector cells of cartilage and bone destruction. These cells show an 'intrinsically' activated and aggressive phenotype that results in the increased production of matrix-degrading enzymes and adhesion molecules, and is conserved over long-term passage in vitro. The three main mechanisms of epigenetic control-DNA methylation, histone modifications and microrNA activity-interact in the development of the rAsF phenotype. The extent of global DNA methylation is reduced in synoviocytes in situ and rAsFs in vitro. in addition, histone hyperacetylation occurs and specific microrNAs are expressed in rAsFs. Normal synovial fibroblasts cultured in a hypomethylating milieu acquire an activated phenotype similar to that of rAsFs. These findings suggest that epigenetic control, in particular the control of DNA methylation, is deficient in rAsFs. Genome-wide analyses of the epigenome will enable the detection of additional genes involved in the pathogenesis of rheumatoid arthritis, the identification of epigenetic biomarkers, and potentially the development of a therapeutic regimen that targets activated rAsFs.
Introduction
Diseases such as cardiovascular, metabolic, musculo skeletal and hematopoietic disorders, which can be attributed to the interaction between genetic and environ mental factors as well as to processes of aging, are highly prevalent in industrialized nations and can be associated with a large burden on healthcare resources. Many of these diseases are thought to have a clear epi genetic background, as in pediatric developmental and imprinted diseases, 1, 2 and/or to be influenced by environ mental factors, as in the contribution of smoking to the development of rheumatic diseases and atherosclerosis. 3 Metabolic disorders (for example, obesity and diabetes) 4 and neuro degenerative disorders such as Alzheimer disease and dementia 5 can also have an epigenetic compo nent. The prevalence of some of these diseases differs according to sex; for example, rheumatoid arthritis (RA) is more common in women than in men, whereas athero sclerosis shows the reverse pattern. 6 With aging, these sex related differences become less obvious. An interesting question is whether sex differences in disease prevalences in middleaged adults could be associated with differen tial imprinting of the Xchromosome-an epigenetic pro cess-since one Xchromosome in women should always be inactivated by DNA methylation. In systemic lupus erythematosus, the demethylation of specific sequences in the X chromosome could contribute to the female pre dominance of the disease. CD40LG, which is located on the X chromo some, is demethylated in the CD4 + T cells of women with systemic lupus erythematosus, 7 which leads to the over expression of CD40 ligand on these cells.
The term epigenetics refers to all meiotically and mito tically heritable changes in gene expression that are not coded in the DNA sequence itself. Three inter acting epi genetic mechanisms, namely DNA methylation, histone modification and complementary microRNA (miRNA) binding, initiate and sustain gene silencing and expres sion. These systems integrate genetic background and environmental factors to enable cell adaptation and sur vival ( Figure 1 ). The disruption of one or another of these interacting systems can lead to inappropriate expression or silencing of genes, and result in 'epigenetic diseases' that include various types of cancer and potentially autoimmune disorders. 8 Methylation of DNA prevents the access of transcription factors and inactivates gene transcription. DNA methy lation involves the addition of a methyl group in the 5' position of the cytosine basepair ring, which results in the formation of 5methylcytosine.
9 This enzymatic reac tion is catalyzed by DNA methyltransferase 1 (DNMT1). In somatic cells, DNMT1 is responsible for maintaining methylation patterns during replication in the context of cytosine-phosphate-guanine (CpG) dinucleotides. 10 During embryogenesis, DNA methyltransferases 3a and 3b (DNMT3a and DNMT3b) add new methylation patterns to the initially methylated CpG dinucleotides in the DNA that silence the transcription of specific gene regions.
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Most single CpG dinucleotides in the genome are methy lated, including those in retro transposable elements, Alu sequences and αsatellite repeats. By contrast, genomic regions with a high frequency of CpG di nucleotidestermed CpG islands-remain un methylated. CpG islands in promoter regions of tumorsuppressor genes are, however, methylated and silenced in diseases such reviews as cancer. 12 MethylCpGbinding domain (MBD) pro teins, including MBD1, MeCP2, MBD3, and MBD4, have important roles in the mechanism of DNA methy lation and interact with histone deacetylases to change the chromatin structure. 13 DNA methylation has a fundamental role in cell dif ferentiation, embryonic development, Xchromosome inactivation in women, genomic imprinting, cell repro gramming and the silencing of retroviral elements such as lINe1 (long interspersed nuclear element 1). 8 The DNA methylation machinery is deregulated in several types of pathology, including developmental, inflam matory and autoimmune disorders.
14 In addition to promoter hypermethylation, these diseases can also be caused by mechanisms such as loss of imprinting, deficient DNMT activity (secondary to posttranslational modifications of the protein or through the action of specific miRNAs) or mutation of an MBP. In this Review, we focus on epi genetic control in RA synovial fibroblasts (sFs).
Mesenchymal stem cell differentiation
Mesenchymal stem cells (MsCs) are undifferentiated, multi potent cells that reside in various human tissues and have the potential to differentiate into osteoblasts, chondro cytes, adipocytes, fibroblasts and other cells of mesenchymal origin. In the human body they can be regarded as readily available reservoirs of reparative cells that are capable of mobilizing, proliferating and differen tiating into the appropriate cell type in response to certain environmental signals. 15 MsCs contain an intrinsically predefined, uni directional differentiation program. The develop mental fate of an MsC is, therefore, dependent on the general potential of the cell as well as on micro environmental cues such as stimulation from growth factors. During the normal differentiation of MsCs into fibroblasts, two key transition points are regulated by epi genetic processes: first, the development of MsCs into a transient fibroblastic pheno type, and, second, the termina tion of lineage expansion. Both of these transition points are tightly regulated in space and time. For example, MsCs that develop into adipocytes are epigenetically marked by mosaic hypo methylation of adipo genic pro moters, whereas pro moters in these cells specific to a non adipogenic lineage are hyper methylated. 16 Furthermore, the terminal differen tiation of fibroblastic adipocytes into osteoblasts involves histone modifications. 17 A similar hypothesis is that sFs emerge from MsCs and develop into tissuespecific cells under the influence of the microenvironment and under epigenetic control (Figure 2 ).
Fibroblasts and phenotypic plasticity
Fibroblasts are metabolically active cells that have criti cal roles in the regulation of extracellular matrices, inter stitial fluid volume and pressure, and wound healing. During tissue repair, for instance, fibroblasts undergo a change in state from their normal, relatively quies cent phenotype, in which they are involved in the slow turnover of the extracellular matrix, to a proliferative and whole-epigenome analysis could lead to the discovery of novel genes and ■ epigenetic biomarkers involved in the pathogenesis of rheumatoid arthritis, with potential implications for treatment contractile phenotype termed myofibroblasts. 18 These myo fibroblasts show some of the phenotypic characteristics of smoothmuscle cells
Fibroblasts are thought to develop specific charac teristics in response to their microenvironment; for example, fibroblasts in the skin, spleen, kidney, lung or synovium exhibit different patterns of growth factor release. 18 To produce such characteristics, certain genes are silenced in fibroblasts in some tissues but expressed in those in other tissues. In the synovium, as is the case in Many diseases are associated with deregulation of the injury-repair response and fibroblast function, which leads to an increase or decrease in the deposition of extracellular matrix proteins, altered tissue architecture, impaired func tion and, in some cases, substantial morbidity and mor tality, as in systemic sclerosis. In such cases, the fibroblasts are hypothesized to either not react or overreact to a given stimulus; this incorrect response can have different causes, including deregulated epi genetic control.
Synovial fibroblasts in RA
In RA, a cytokineindependent pathway seems to be responsible for the ongoing joint destruction mediated by sFs. 19 The pathological changes associated with this process include excessive hyperplasia of and an infiltration of inflammatory cells into the synovial tissue. Activated sFs have an important role in the destruction caused by this disease; however, myofibroblasts have also been detected in the RA synovium, which reflects either an activation state or a problem of differentiation. 20 The activated phenotype of RAsFs could be an intrinsic property of these cells, since RAsFs coimplanted with human cartilage into severe, combined immunodeficient (sCID) mice are invasive even in the absence of other cells of the human immune system. 21 This concept is reflected in vitro by, for example, the increased production of matrixdegrading enzymes and adhesion molecules by RAsFs. The 'imprinted' aggres sive and invasive phenotype of RAsFs could be determined by genetic and/or epigenetic backgrounds, perhaps in the context of global genomic hypomethylation. sFs, more so than other types of fibroblasts, acquire pheno typic characteristics that are commonly associ ated with transformed cells, including the capacity for anchorageindependent growth. 22 In contrast to normal sFs or those from patients with osteoarthritis, sFs from patients with RA show 'spontaneous' activities that are associated with an aggressive phenotype. 21, [23] [24] [25] For example, these cells show upregulated expression of proto oncogenes, 21 specific matrix degrading enzymes, 23 adhe sion molecules, 24 and cytokines. 25 These observations of an intrinsically activated cellular phenotype prompted us and others to search for possibly causative epigenetic modifications ( Figure 3 ). Histone acetylation is increased in RAsFs and specific miRNAs are upregulated, 26, 27 which suggests that other epigenetic pathways as well as genomic methylation are altered.
Epigenetic processes in the pathogenesis of RA
Global genomic hypomethylation our group and others 28, 29 have reported that the endoge nous retroviral element lINe1 is reactivated in the RA synovial lining and at sites of cartilage and bone invasion. Most lINe1 elements are retrotranspositiondefective. A fulllength lINe1 messenger RNA has been isolated from RAsFs that encoded an intact open reading frame (oRF) 1; oRF2, however, contained multiple stop codons, 30 which rendered the entire element retro transpositiondefective. We suggested that the expression of lINe1 proteins in RAsFs is associated with a partially hypomethylated promoter region. The degree of hypomethylation in the lINe1 promoter is under investigation. 31 In normal cells, repetitive sequences such as lINe1, Alu, and αsatellite repeats are silenced by methylation, and their expression can reflect global DNA hypomethylation. 32 This general cellular mechanism has important consequences in RAsFs because methy lation markers apparently cannot be correctly trans mitted from mother to daughter cells during proliferation. The incorrect methy lation patterns induce either cellular de differentiation or a completely new phenotype.
These reports suggest that global genomic hypo methy lation has a role in the pathogenesis of RA, and that genes normally silenced by methylation might contrib ute to the activated phenotype of RAsFs. For example, the gene that encodes interleukin (Il)6 could be regu lated by demethylation of a single CpG site in the IL6 promoter region. 33 
DNA methyltransferases
In somatic cells, DNMT1 is the predominant DNA methyl transferase. Reduction of DNMT1 levels leads to hypo methylation, genomic instability, and tumorigenesis. 34 The direct interaction between DNMT1 and proliferating cell 35 other diseases have also been associated with decreased activity of DNMTs. For example, ICF (immuno deficiency, centromeric region instability and facial anomalies) syn drome is an autosomalrecessive disease that is associ ated with abnormal DNA methylation and mutations in the cata lytic domain of DNMT3b. 36 The disease causes immuno deficiency as a result of reduced immuno globulin levels, and involves chromosomal instability due to hypomethylation of satellite repeats.
Influence of a hypomethylating milieu
With regard to the potential role of genomic hypo methylation in generating aggressive sFs, we hypothe sized that the RAsF phenotype could be mimicked in normal sFs by inhibition of DNMT1, for example by chronic treatment with a nontoxic dose of the DNA methyl transferase inhibitor azacytidine. 35, 37 In the study, about 200 genes were found to be upregulated more than twofold by DNA hypomethylation, which was associated with enhanced protein expression in most cases. Furthermore, hypomethylation led to irreversible phenotypic changes in normal sFs, so that they resembled activated RAsFs. Proinflammatory cytokines such as tumor necrosis factor, Il1β, and Il6 have multiple influences on the patho genesis of RA; Il1β 38 and Il6 39 can also affect genomic methylation. Il6 stimulates translocation of DNMT1 to the nucleus. 40 An important point to note is that proinflam matory cytokines and growth factors accelerate the cell cycle. During DNA replication, normal sFs recruit DNMT1, 37 which has been shown by Chuang and col leagues (in another system) to interact with proliferat ing cell nuclear antigen at the DNA replication fork to ensure the correct setting of methylation markers. 41 In RAsFs, however, DNMT1 might be deficient, which would result in a gradual genomic hypo methylation, a process that would worsen with each cell cycle. A similar process has been reported in tumor cells, in which increased cell pro liferation and global genomic hypomethylation are accom panied by a relative deficiency in DNMT1. 42 Reduced levels of DNMT1 can, however, also occur in normal cells, as in terminal differentiation of neuronal cells and myo blasts. 43 In RAsFs, then, a relative deficiency of DNMT1 could lead to loss of methylation markers in daughter cells, and induce the irreversible differentiation into an aggressive phenotype. IL6 hypomethylation has also been observed in peripheral blood mononuclear cells from patients with RA:
33 the demethylation of a single CpG site in the promoter region of IL6 could be responsible for the overexpression of Il6 in patients with RA.
hypermethylation of specific promoters our work raises the question of whether global genomic hypomethylation is accompanied by or followed by specific promoter hypermethylation, as is the case in various tumors. 12, 44 At least one such example has been reported in the literature-hypermethylation silences the gene TNFRSF25, which encodes death domain receptor 3 (DDR3; also known as tumor necrosis factor receptor superfamily member 25). 45 The promoter region of TNFRSF25 contains many CpG motifs, including a CpG island that is specifically hypermethylated in synovial cells isolated from patients with RA. Assays showed that this CpG island is essential for transactivation of TNFRSF25, and that forced hypermethylation of this CpG island in vitro (by means of the bacterial methylase sss I) inhibits expres sion of TNFRSF25. Furthermore, expression of DDR3 protein was downmodulated in association with methy lation of this promoter CpG island in RAsFs. 45 This mecha nism could explain, at least in part, the reported relative resistance to apoptosis of RAsFs in certain patients. 19 
Investigating DNA methylation
The methods used to investigate DNA methylation can be divided into three categories: global methylation analy sis, singlelocus analysis and wholeepigenome analysis (Figure 4) . 46 Global changes in DNA methylation are studied mainly by flow cytometry and immunohistochemistry (Figure 4a) , which have been used to demonstrate DNA hypomethylation in RA synovium.
Analysis of a single epigenetic locus typically uses the technique of bisulfite modification sequencing (Figure 4b) . 47 This method detects and quantifies methy lation changes in, for example, CpG sites of gene pro moters. The assay is based on bisulfitemediated conversion of unmethylated cytosine residues into uracil, whereas methylated cytosines remain unchanged; after polymerase chain reaction (PCR) amplification, unchanged cytosine residues in the nucleotide sequence indicate the presence of methylated cytosines, whereas conversion from cytosine reviews into thymidine indicates an unmethylated cytosine. This method has been used to demonstrate that lINe1 promoters are hypomethylated in RAsFs. 28 A related singlelocus analysis technique used in clinical screen ing is pyrosequencing, 48 a new DNA sequencing method based on detection of a light signal when nucleotides are incorporated into the DNA. Following PCR amplification of bisulfitetreated DNA, pyrosequencing of the specific product quantifies methylation by detecting each time a cytosine base is incorporated instead of a thymidine base. The advantages of this method are that multiple samples can be analyzed at the same time and that sitespecific, quantitative, methylation information is obtained.
Alternatively, DNA methylation at a single locus can be analyzed in biopsy samples by use of methylationsensitive endonucleases. 49 Multiple enzymes that cleave different CpG sites in the promoter can be used to analyze DNA samples obtained from biopsy specimens. specific primers are designed to cover the CpG sites in the given gene and PCR is performed. Methylated DNA is resistant to enzy matic cleavage and will be amplified by PCR. Quantitative realtime PCR can be used.
Novel approaches to assessments of DNA methylation focus on global analyses of the epigenome by use of tiling arrays and CpGisland promoter arrays (Figure 4c ). 50 Tiling arrays contain sets of oligonucleotides that span the entire human genome, or at least certain chromosomal regions of interest. CpGisland promoter arrays are based on probes located in the promoter regions of the human genome. In the study of RAsFs, progression from single locus analysis to wholeepigenome analyses in the near future will be an essential step.
Future directions
one of the most challenging problems in the field of epi genetics is the generation of detailed functional maps of the epigenome in health and disease, as well as in different cell and tissue types. This information will allow clini cians to tailor therapeutic regimens to the needs of an individual patient. An epigenetic disorder that affects, for example, the promoter of a given gene requires a thera peutic stra tegy different to that used to treat a disease with similar symptoms that is caused by a genetic mutation of the same gene. Differential diagnosis of such disorders, on the basis of epigenetic biomarker profiles in specific subgroups of patients, will, in turn, enable the development of drugs that target the defective epigenetic mechanism.
until recently, DNA methylation of promoter regions was investigated by timeconsuming methods, such as bisulfitemodification sequencing, which are not suitable for largescale analyses. With the rapid development of microarray platforms and highthroughput sequencing techniques, a global analysis of the epigenome to produce a detailed cartogram of each chromosome is now possible. 49 Information gathered by this approach should, however, be verified and complemented by detailed analyses that involve other techniques, such as bisulfitemodification sequencing, methylated CpG island recovery assay and methylatedDNA immunoprecipitation assays. 51, 52 Currently, the epigenome is not analyzed systematically, and epigenetic changes have not been assessed within the reviews Human Genome Project. evidence indicates, however, that several illnesses, including RA, are linked to specific epigenetic processes and profiles 51 which, in the case of RA, might explain its late onset and the differences in age and sex distribution, as well as its progressive nature. Moreover, epigenetic alterations probably underpin the role of environmental factors in the pathogenesis of diseases in genetically susceptible individuals, and thus might broaden the scope of new therapies.
Conclusions
The RA synovium contains cells of various types that exhibit hypomethylated DNA. Among these, RAsFs contain fewer 5methylcytosine residues than normal sFs and this difference is conserved over longterm culture in vitro. Furthermore, expression of lINe1 messenger RNA and proteins are associated with hypomethylated promoters. This characteristic reflects a global state of DNA hypomethylation, which has important conse quences for RAsFs, since an important mechanism of epigenetic control seems to be defective. As a demon stration of the consequences of this loss of epigenetic control, inhibition of DNMT1 expression in normal sFs is sufficient to produce an aggressive phenotype that includes upregulated expression of matrixdegrading enzymes and adhesion molecules. Indeed, the level of DNMT1 in proliferat ing RAsFs is lower than that in normal sFs. Thus, during DNA replication in RAsFs, the correct methylation patterns are not transmitted, or incorrect patterns are transmitted, from mother cells to daughter cells. Consequently, genes in the daughter cells that should be silenced are expressed. This mechanism explains in great part the high number of transcripts that are upregulated in RAsFs.
several mechanisms can lead to the upregulation of gene transcripts as a consequence of DNA hypomethy lation, either directly, through the loss of methylation markers in gene promoter regions, or indirectly, through the action of transcription factors or signaling pathways that are modulated by methylation. since DNA methy lation interacts with histone modifications and miRNA activity, these other epigenetic mechanisms could also be affected and could contribute to development of the aggressive RAsF phenotype. The interplay between these epigenetic mechanisms should be investigated in this context. The progression from singlelocus analysis of DNA methylation to wholeepigenome analysis will be important as the latter will enable the discovery of novel genes and epigenetic biomarkers involved in the pathogenesis of RA, and will help to expand the treatment options for this disease.
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